1. Scrip
  2. >>R&D

Targeting Exciting Inflammasome Field, NodThera Raises $55m

Among Pioneers Of NLRP3 Inhibitors

 
• By Andrew McConaghie

UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.

Research_Lab
Research into NLRP3 inhibitors has gained momentum in the last few years

UK-headquartered NodThera Ltd. has raised $55m from investors as it pursues the promising field of small molecule NLRP3 inflammasome inhibitors.

The company is one of a small number of start-up companies looking to pioneer research into the field, and its small molecule drug platform could target conditions from fibrosis (including NASH

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip